Enteric coating for targeting the duodenum
A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.
1. A system for targeted delivery of a medicament to a gastrointestinal (GI) tract of a subject, comprising:
(a) a medicament comprising biotherapeutics and/or nucleic acids;
(b) a mucoadhesive layer surrounding the medicament, wherein the mucoadhesive layer is coated onto the medicament, wherein the mucoadhesive layer comprises one of pectin, sodium caboxymethyl cellulose, or carbopol; and
(c) an enteric coating encasing the medicament and mucoadhesive layer, wherein the enteric coating comprises:
a first layer comprising a polymer degradable by a pH of the GI tract, wherein the first layer is adjacent the mucoadhesive layer, wherein the polymer is selected from the group consisting of polylactic acid, nylon, polyester, and polyvinyl alcohol; and
a second layer comprising a wax material digestible by a lipase, wherein the wax material comprises one of coconut oil or bees wax, wherein the second layer is an outer layer;
wherein the enteric coating dissolves in less than one minute in a human duodenum at a dissolution rate from 5 (mg/cm 3 )/min to 26 (mg/cm 3 )/min.
2. The system for targeted delivery of a medicament of claim 1 , wherein a weight ratio of the polymer degradable by pH and the wax material digestible by lipase is from 0.3:1 to 1:1.
3. The system for targeted delivery of a medicament of claim 1 , wherein the enteric coating encasing the medicament and mucoadhesive layer does not degrade at a pH of 1.5 to 4.0 in a human stomach.
4. The system for targeted delivery of a medicament of claim 1 , wherein the mucoadhesive layer adheres to a wall of the GI tract of the subject.
5. The system for targeted delivery of a medicament of claim 1 , wherein the enteric coating is degraded in less than one minute in a human duodenum at a dissolution rate from 5 (mg/cm 3 )/min to 26 (mg/cm 3 )/min exposing the mucoadhesive layer and the medicament to a wall of the GI tract.
6. The system for targeted delivery of a medicament of claim 1 , further comprising:
(d) a medicament needle system for delivering the medicament to the GI tract; and
(e) an expanding element expandable in response to absorbing fluid for driving the medicament and medicament needle system out of the mucoadhesive layer.
7. A method of administering a medicament directly to the gastrointestinal (GI) tract of a subject, administering to the subject the system of claim 1 .
8. The method of claim 7 , wherein the system is administered orally to the subject.
9. The method of claim 7 , wherein the medicament is administered selectively to the GI tract of the subject.
10. The method of claim 9 , wherein the medicament is administered selectively to the duodenum of the subject.
11. A system for targeted delivery of a medicament to a gastrointestinal (GI) tract of a subject, comprising:
(a) a medicament comprising biotherapeutics and/or nucleic acids, wherein the mucoadhesive layer comprises one of pectin, sodium caboxymethyl cellulose, or carbopol;
(b) a medicament needle system for delivering the medicament to the GI tract;
(c) a capsule at least partially encasing the medicament needle system; wherein the capsule comprises:
a mucoadhesive layer surrounding the medicament needle system; and
an enteric coating encasing the mucoadhesive layer, wherein the enteric coating comprises:
a first layer comprising a polymer degradable by a pH of the GI tract, wherein the first layer is adjacent the mucoadhesive layer, wherein the polymer is selected from the group consisting of polylactic acid, nylon, polyester, or polyvinyl alcohol; and
a second layer comprising a wax material digestible by a lipase, wherein the wax material comprises one of coconut oil or bees wax, wherein the second layer is an outer layer;
wherein the enteric coating degrades in less than one minute in a human duodenum at a dissolution rate from 5 (mg/cm 3 )/min to 26 (mg/cm 3 )/min; and
(d) an expanding element expandable in response to absorbing fluid for driving the medicament and medicament needle system out of the capsule.
12. The system of claim 11 , wherein the capsule at least partially surrounds the medicament and the capsule defines a first opening and a second opening, the first opening adjacent the medicament needle system and the second opening adjacent the expanding element.
13. The system of claim 12 , wherein the enteric coating closes the first opening and the second opening.
14. The system of claim 11 , wherein the expanding element comprises a super absorbent material configured to expand up to or greater than 400 times in size.
15. The system of claim 14 , wherein the super absorbent material comprises polyacrylate.
16. The system of claim 14 , wherein the super absorbent material is bio-compatible and expands in volume as fluid is absorbed by the super absorbent material.
17. The system of claim 16 , wherein the expanding element further comprises a piston and wherein the super absorbent material and the medicament needle system are on opposing sides of the piston.